CENTURY THERAPEUTICS
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer. The company's genetically-engineered, iPSC-derived immune effector cell products are designed to specifically target hematologic and solid cancers by harnessing the power of adult stem cells, providing patients with an unparalleled opportunity to advance the course of cancer care.
CENTURY THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2018-03-05
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.centurytx.com
Total Employee:
101+
Status:
Active
Total Funding:
560 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS GoDaddy DNS Amazon Virginia Region Barracuda Networks
Similar Organizations
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Novita Pharmaceuticals
Novita Pharmaceuticals is a developer of therapeutic drugs for the treatment of cancer.
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-06-23 | Empirica Therapeutics | Empirica Therapeutics acquired by Century Therapeutics | N/A |
Investors List
Bristol Myers Squibb
Bristol Myers Squibb investment in Post-IPO Equity - Century Therapeutics
Logos Capital
Logos Capital investment in Series C - Century Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series C - Century Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Century Therapeutics
Marshall Wace
Marshall Wace investment in Series C - Century Therapeutics
Qatar Investment Authority
Qatar Investment Authority investment in Series C - Century Therapeutics
Casdin Capital
Casdin Capital investment in Series C - Century Therapeutics
OrbiMed
OrbiMed investment in Series C - Century Therapeutics
Versant Ventures
Versant Ventures investment in Series C - Century Therapeutics
Avidity Partners
Avidity Partners investment in Series C - Century Therapeutics
Official Site Inspections
http://www.centurytx.com Semrush global rank: 4.98 M Semrush visits lastest month: 1.7 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Century Therapeutics"
About | Century Therapeutics
Century Therapeutics is an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein โฆSee details»
Corporate Overview - investors.centurytx.com
Century Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +1 267 857 1080 Century Therapeutics builds an allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein โฆSee details»
Join Us - Century Therapeutics
I am proud to be part of an organization whose values, mission and culture align with my personal and professional objectives. Shelby . Senior Associate Scientist โ It is incredibly exciting to see โฆSee details»
Century Therapeutics, Inc | LinkedIn
Century Therapeutics, Inc | 22,520 followers on LinkedIn. Harnessing the power of adult stem cells to develop curative therapies for cancer and autoimmune diseases | Our genetically โฆSee details»
Century Therapeutics to Present at the Piper Sandler 36th Annual ...
Nov 26, 2024 For more information on Century Therapeutics please visit www.centurytx.com. For More Information: Investor Relations & Media Contacts. Century Therapeutics Katja โฆSee details»
Century Therapeutics Announces Internal Portfolio Prioritization to ...
Jan 5, 2023 โAs our confidence in the disruptive potential of our technology platform and prioritized pipeline programs continues to increase, we have implemented these cost saving โฆSee details»
Century Therapeutics Canada - Synapse Life Science Consortium
Century Therapeutics is developing novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies. Our commitment to developing accessible cell โฆSee details»
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., โฆ
Nov 9, 2023 IPSC_CEO Headshot. Brent Pfeiffenberger, Pharm.D., MBA. PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative โฆSee details»
Contact Us - Century Therapeutics
[email protected] . CONTACT US FOR MEDIA INQUIRIES [email protected] . All Other Inquiries *Optional. CORPORATE HEADQUARTERS . Philadelphia . Century Therapeutics, โฆSee details»
Century Therapeutics Announces Leadership Changes
Apr 12, 2023 For more information on Century Therapeutics please visit www.centurytx.com. Century Therapeutics Forward-Looking Statement. This press release contains forward โฆSee details»
Science - Century Therapeutics
Century is leveraging the unlimited self-renewing capacity of iPSCs and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with โฆSee details»
Century Therapeutics Expands Board of Directors with Key โฆ
PHILADELPHIA, May 5, 2021 /PRNewswire/ -- Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno โฆSee details»
Century Therapeutics Strengthens Leadership Team with โฆ
Sep 26, 2024 For more information on Century Therapeutics please visit www.centurytx.com. Century Therapeutics Forward-Looking Statement. This press release contains forward โฆSee details»
Bristol Myers Squibb - Century Therapeutics and Bristol Myers โฆ
Jan 10, 2022 For more information on Century Therapeutics please visit www.centurytx.com. Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking Statements This โฆSee details»
Century Therapeutics Reports Full Year 2022 Financial Results and ...
Mar 16, 2023 - Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash, cash equivalents, and investments of $367.4 โฆSee details»
Pipeline - Century Therapeutics
CNTY-108 is an iPSC-derived CD19 targeting allogeneic iNK or ฮณฮด iT product candidate for autoimmune diseases. It is engineered with an augmented suite of Centuryโs Allo-Evasionโข โฆSee details»
Clinical Trials - Century Therapeutics
ELiPSE-1: Phase 1 Clinical Trial. A multicenter, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CNTY-101 in patients with relapsed or refractory โฆSee details»
Century Therapeutics Reports Fourth Quarter and Year-end 2021 โฆ
Mar 17, 2022 IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence after IND โฆSee details»